Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Crossref

1. Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C

- Mahdiyar Pouresmaeeli

- Seyed Moayed Alavian

- Maryam Keshvari

- Shima Salimi

- Leila Mehrnoush

2. Vitamin D in Standard HCV Regimen (PEG-Interferon Plus Ribavirin), Its Effect on the Early Virologic Response Rate: A Clinical Trial

- Hasan Vosoghinia

- Abbas Esmaeilzadeh

- Azita Ganji

- Seyed Mousal-Reza Hosseini

- Saeid Amel Jamehdar

- Maryam Salehi

- Ali Bahari

- Omid Ghanaei

- Maryam Sahebari

- Farnood Rajabzadeh

- Kamran Ghaffarzadehgan

- Ladan Goshayeshi

3. Some Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C

- Reza Karbasi-Afshar

- Amin Saburi

4. lasma Zinc Level in Hepatitis C Patients With or Without Beta Thalassemia Major; Is There Any Difference?

- Mohammad Abbasinazari

- Bita Behnava

- Yunes Panahi

- Azita Hajhossein Talasaz

- Shima Salimi

- Maryam Keshvari

- Leila Mehrnoush

- Pegah karim

- Mohammad Gholami Fesharaki

- Mansour Asgharinia

- Seyed Moayed Alavian

5. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline

- Seyed Moayed Alavian

- Behzad Hajarizadeh

- Kamran Bagheri Lankarani

- Heidar Sharafi

- Nasser Ebrahimi Daryani

- Shahin Merat

- Minoo Mohraz

- Masoud Mardani

- Mohamad Reza Fattahi

- Hossein Poustchi

- Mehri Nikbin

- Mahmood Nabavi

- Peyman Adibi

- Masood Ziaee

- Bita Behnava

- Mohammad Saeid Rezaee-Zavareh

- Massimo Colombo

- Hatef Massoumi

- Abdul Rahman Bizri

- Bijan Eghtesad

- Majid Amiri

- Ali Namvar

- Khashayar Hesamizadeh

- Reza Malekzadeh

6. Predicting the Outcomes of Combination Therapy in Patients With Chronic Hepatitis C Using Artificial Neural Network

- Forough Sargolzaee Aval

- Nazanin Behnaz

- Mohamad Reza Raoufy

- Seyed Moayed Alavian

7. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients

- Arghavan Haj-sheykholeslami

8. The Evaluation of Interferon Lambda 4 rs368234815 as a Predictor Factor in Treated Patients with Chronic Hepatitis C Genotype 1a Infection

- Shahram Jalilian

- Seyed Mahmoud Latifi

- Manoochehr Makvandi

- Ali Teimoori

- Azarakhsh Azaran

- Mehdi Parsanahad

- Gholamabas Kayedani

9. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients

- Farah Bokharaei-Salim

- Hossein Keyvani

- Mostafa Salehi-Vaziri

- Farzin Sadeghi

- Seyed Hamidreza Monavari

- Leila Mehrnoush

- Seyed Moayed Alavian

10. Hepatitis C Therapy – Related Haematological Side Effects are Associated with Treatment Outcome / Hematološka Neželjena Dejstva Terapije Hepatitisa C Su Povezana Sa Ishodom Lecenja

- Vuk R. Vukovic

- Dejan Baskic

- Zeljko Mijailovic

- Predrag Djurdjevic

11. Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013

- Nasser Ebrahimi Daryani

- Seyed Moayed Alavian

- Mohammad Hossein Somi

- Mohammad Torabi-Nami

12. Psychiatric side effects of pegylated interferon‑α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta‑analysis

- Lotfollah Davoodi

- Babak Masoum

- Mahmood Moosazadeh

- Hamed Jafarpour

- Mohammad Haghshenas

- Tahoora Mousavi

13. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C

- Farzin Sadeghi

- Farah Bokharaei-Salim

- Mostafa Salehi-Vaziri

- Seyed Hamidreza Monavari

- Seyed Moayed Alavian

- Shima Salimi

- Rouhollah Vahabpour

- Hossein Keyvani

14. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population

- Amitis Ramezani

- Kazem Baesi

- Mohammad Banifazl

- Minoo Mohraz

- Farzin Khorvash

- Majid Yaran

- Payam Tabarsi

- Amir hosein Dalirrooyfard

- Fatemeh Motevalli

- Anahita Bavand

- Arezoo Aghakhani

15. Adherence to Chronic Hepatitis C Treatment Regimen: First Report From a Referral Center in Iran

- Saeedeh Ravi

- Mohsen Nasiri Toosi

- Iman Karimzadeh

- Mehdi Ahadi-Barzoki

- Hossein Khalili

16. Epidemiology of hepatitis C virus in Iran

- Reza Taherkhani

17. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C

- Parvaneh Sedighimehr

- Shiva Irani

- Fatemeh Sakhaee

- Farzam Vaziri

- Mohammadreza Aghasadeghi

- Seyed Mehdi Sadat

- Fatemeh Rahimi Jamnani

- Abolfazl Fateh

- Seyed Davar Siadat

18. Determination of Whether Vitiligo is a Contraindication to Interferon Therapy in Chronic Hepatitis C

- Seyed Moayed Alavian

19. Prevalence of Hepatitis C Virus Genotypes Among Patients in Countries of the Eastern Mediterranean Regional Office of WHO (EMRO): A Systematic Review and Meta-Analysis

- Farzin Sadeghi

- Mostafa Salehi-Vaziri

- Amir Almasi-Hashiani

- Mohammad Gholami-Fesharaki

- Reza Pakzad

- Seyed Moayed Alavian

20. Risk Factors for Migraine Attacks in Patients Undergoing Treatment for Hepatitis C

- Razie Salesi

- Asieh Salesi

- Faraidoon Haghdoost

- Seyed Moayed Alavian